Cite
Borst GR, Kumareswaran R, Yücel H, et al. Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget. 2017;8(50):87638-87646doi: 10.18632/oncotarget.20936.
Borst, G. R., Kumareswaran, R., Yücel, H., Telli, S., Do, T., McKee, T., Zafarana, G., Jonkers, J., Verheij, M., O'Connor, M. J., Rottenberg, S., & Bristow, R. G. (2017). Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget, 8(50), 87638-87646. https://doi.org/10.18632/oncotarget.20936
Borst, Gerben R, et al. "Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model." Oncotarget vol. 8,50 (2017): 87638-87646. doi: https://doi.org/10.18632/oncotarget.20936
Borst GR, Kumareswaran R, Yücel H, Telli S, Do T, McKee T, Zafarana G, Jonkers J, Verheij M, O'Connor MJ, Rottenberg S, Bristow RG. Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget. 2017 Sep 15;8(50):87638-87646. doi: 10.18632/oncotarget.20936. eCollection 2017 Oct 20. PMID: 29152107; PMCID: PMC5675659.
Copy
Download .nbib